| For: | Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i7/1091.htm |
| Number | Citing Articles |
| 1 |
Amy L. Lightner, Scott A. Strong. The ASCRS Textbook of Colon and Rectal Surgery. 2022; doi: 10.1007/978-3-030-66049-9_45
|
| 2 |
Niharika Nalagatla, Katherine Falloon, Gloria Tran, Nienke Z. Borren, Danny Avalos, Jay Luther, Francis Colizzo, John Garber, Hamed Khalili, Joanna Melia, Matthew Bohm, Ashwin N. Ananthakrishnan. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clinical Gastroenterology and Hepatology 2019; 17(3) doi: 10.1016/j.cgh.2018.06.031
|
| 3 |
David T. Rubin, Ashwin N. Ananthakrishnan, Corey A. Siegel, Edward L. Barnes, Millie D. Long. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. American Journal of Gastroenterology 2025; 120(6) doi: 10.14309/ajg.0000000000003463
|
| 4 |
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W. Leong. Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2024; 59(11) doi: 10.1111/apt.18006
|
| 5 |
Sayar Süleyman, Pala Emin, Aykut Hüseyin, Ak Çağatay, Ölmez Şehmus, Özdil Kamil. Prognostic Utility of Albumin and the C-Reactive Protein-to-Albumin Ratio for Predicting Intravenous Steroid Response in Acute Severe Ulcerative Colitis. Journal of Clinical Medicine 2026; 15(7) doi: 10.3390/jcm15072730
|
| 6 |
Javier P. Gisbert, María Chaparro. Acute severe ulcerative colitis: State of the art treatment. Best Practice & Research Clinical Gastroenterology 2018; doi: 10.1016/j.bpg.2018.05.007
|
| 7 |
Kymberley Thorne, Laith Alrubaiy, Ashley Akbari, David G. Samuel, Sian Morrison-Rees, Stephen E. Roberts. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin. European Journal of Gastroenterology & Hepatology 2016; 28(4) doi: 10.1097/MEG.0000000000000568
|
| 8 |
Jeff Chang, Rupert WL Leong. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opinion on Biological Therapy 2014; 14(1) doi: 10.1517/14712598.2014.853738
|
| 9 |
Matthew C Choy, Dean Seah, David M Faleck, Shailja C Shah, Che-Yung Chao, Yoon-Kyo An, Graham Radford-Smith, Talat Bessissow, Marla C Dubinsky, Alexander C Ford, Leonid Churilov, Neville D Yeomans, Peter P De Cruz. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2019; 25(7) doi: 10.1093/ibd/izy383
|
| 10 |
|
| 11 |
Enayatullah Baki, Philipp Zwickel, Anna Zawierucha, Robert Ehehalt, Daniel Gotthardt, Wolfgang Stremmel, Annika Gauss. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World Journal of Gastroenterology 2015; 21(11): 3282-3290 doi: 10.3748/wjg.v21.i11.3282
|
| 12 |
A. Croft, A. Walsh, J. Doecke, G. Radford-Smith. Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab? Author's reply. Alimentary Pharmacology & Therapeutics 2013; 38(8) doi: 10.1111/apt.12475
|
| 13 |
Bikash Devaraj, Andreas M. Kaiser. Surgical Management of Ulcerative Colitis in the Era of Biologicals. Inflammatory Bowel Diseases 2015; 21(1) doi: 10.1097/MIB.0000000000000178
|
| 14 |
Christopher F. D. Li Wai Suen, Matthew C. Choy, Peter De Cruz. What to do when traditional rescue therapies fail in acute severe ulcerative colitis. Intestinal Research 2024; 22(4) doi: 10.5217/ir.2024.00003
|
| 15 |
Christopher F D Li Wai Suen, Dean Seah, Matthew C Choy, Peter De Cruz. Factors Associated With Response to Rescue Therapy in Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2024; 30(8) doi: 10.1093/ibd/izad183
|
| 16 |
Jeanne Tung, Felicity T. Enders, Edward V. Loftus. Response to: Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. Journal of Crohn's and Colitis 2014; 8(10) doi: 10.1016/j.crohns.2014.02.020
|
| 17 |
Yoichiro Nuki, Motohiro Esaki, Kouichi Asano, Yuji Maehata, Junji Umeno, Tomohiko Moriyama, Shotaro Nakamura, Takayuki Matsumoto, Takanari Kitazono. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scandinavian Journal of Gastroenterology 2016; 51(6) doi: 10.3109/00365521.2016.1138239
|
| 18 |
Javier P Gisbert, María José García, María Chaparro. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review. Journal of Crohn's and Colitis 2023; 17(6) doi: 10.1093/ecco-jcc/jjad004
|
| 19 |
J.‐H. Chen, J. M. Andrews, V. Kariyawasam, N. Moran, P. Gounder, G. Collins, A. J. Walsh, S. Connor, T. W. T. Lee, C. E. Koh, J. Chang, S. Paramsothy, S. Tattersall, D. A. Lemberg, G. Radford‐Smith, I. C. Lawrance, A. McLachlan, G. T. Moore, C. Corte, P. Katelaris, R. W. Leong. Review article: acute severe ulcerative colitis – evidence‐based consensus statements. Alimentary Pharmacology & Therapeutics 2016; 44(2) doi: 10.1111/apt.13670
|
| 20 |
Marina Aloi, Giulia D’Arcangelo, Martina Capponi, Federica Nuti, Francesca Vassallo, Fortunata Civitelli, Salvatore Oliva, Giuseppe Pagliaro, Salvatore Cucchiara. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy. Digestive and Liver Disease 2015; 47(6) doi: 10.1016/j.dld.2015.01.156
|
| 21 |
M. B. Sprakes, P. J. Hamlin. Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?. Alimentary Pharmacology & Therapeutics 2013; 38(8) doi: 10.1111/apt.12436
|
| 22 |
Catherine Dong, Marie Metzger, Einar Holsbø, Vittorio Perduca, Franck Carbonnel. Systematic review with meta‐analysis: mortality in acute severe ulcerative colitis. Alimentary Pharmacology & Therapeutics 2020; 51(1) doi: 10.1111/apt.15592
|
| 23 |
Marcus Harbord, Rami Eliakim, Dominik Bettenworth, Konstantinos Karmiris, Konstantinos Katsanos, Uri Kopylov, Torsten Kucharzik, Tamás Molnár, Tim Raine, Shaji Sebastian, Helena Tavares de Sousa, Axel Dignass, Franck Carbonnel. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017; 11(7) doi: 10.1093/ecco-jcc/jjx009
|
| 24 |
David T. Rubin, Ashwin N. Ananthakrishnan, Corey A. Siegel, Bryan G. Sauer, Millie D. Long. ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology 2019; 114(3) doi: 10.14309/ajg.0000000000000152
|
| 25 |
G. Pellino, D. S. Keller, G. M. Sampietro, M. Carvello, V. Celentano, C. Coco, F. Colombo, A. Geccherle, G. Luglio, M. Rottoli, M. Scarpa, G. Sciaudone, G. Sica, L. Sofo, R. Zinicola, S. Leone, S. Danese, A. Spinelli, G. Delaini, F. Selvaggi, Imerio Angriman, Paola Caprino, Francesca Di Candido, Mirko Di Ruscio, Silvio Laureti, Gilberto Poggioli, Gianluca Rizzo, Giulia Roda, Franco Sacchetti, Stefano Scaringi, Bruno Sensi, Angela Variola, Committee Gianluca Pellino, Deborah S. Keller, Gianluca M. Sampietro, Salvatore Leone, Silvio Danese, Antonino Spinelli, GianGaetano Delaini, Francesco Selvaggi. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Techniques in Coloproctology 2020; 24(5) doi: 10.1007/s10151-020-02175-z
|